Login
GSK plc logo

GSK plc

gsk.com

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).

Financial Snapshot

Revenue
TTM
$33.20B
Gross Margin
TTM
73.63%
Net Income
TTM
$4.821B
Current Assets
2026 Q2
$17.56B
Current Liabilities
2026 Q2
$21.53B
Current Ratio
2026 Q2
81.54%
Total Assets
2026 Q2
$61.74B
Total Liabilities
2026 Q2
$44.09B
Book Value
2026 Q2
17.65B
Cash
2026 Q2
$3.105B
P/E
TTM
16.12
Free Cash Flow
TTM
$5.331B

Stock Price

Loading...
Market Cap: $77.736 Billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support